Rapport Therapeutics, Inc. RAPP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20M— | —— | —— | —— | $0— | ||
| $32.72M+67.2% | $30.26M+75.9% | $22.28M+43.3% | $22.68M+44.6% | $19.57M+56.5% | ||
| $11.5M+52.6% | —— | —— | —— | $7.54M— | ||
| $44.22M+63.1% | $38.51M+63.7% | $29.99M+38.6% | $29.5M+41.8% | $27.11M+58.6% | ||
| $44.22M+63.1% | $38.51M+63.7% | $29.99M+38.6% | $29.5M+41.8% | $27.11M+58.6% | ||
| -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% | -$29.5M-41.8% | -$27.11M-58.6% | ||
| -121.1%— | —— | —— | —— | —— | ||
| $4.36M+43.1% | $4.75M+34.0% | $3.06M-25.4% | $2.76M+3.2% | $3.05M+67.8% | ||
| $4.36M+43.1% | $4.75M+34.0% | $3.06M-25.4% | $2.76M+3.2% | $3.05M+155% | ||
| -$19.86M+17.5% | -$33.76M-69.0% | -$26.93M-53.5% | -$26.73M-47.5% | -$24.06M-6.1% | ||
| -99.3%— | —— | —— | —— | —— | ||
| -$0.42+38.2% | -$0.71-492% | -$0.71-42.0% | -$0.75+55.9% | -$0.68+93.9% | ||
| -$0.42+38.2% | -$0.71-492% | -$0.71-42.0% | -$0.75+55.9% | -$0.68+93.9% | ||
| 47.2M+33.9% | 38.9M+87.7% | 37.9M+8.8% | 35.4M+232% | 35.3M+1,623% | ||
| 47.2M+33.9% | 38.9M+87.7% | 37.9M+8.8% | 35.4M+232% | 35.3M+1,623% | ||
| -$20.91M+11.5% | -$33.36M-59.6% | -$26.7M-57.5% | -$26.71M-47.2% | -$23.64M-3.5% | ||
| -$1.05M-346% | $401K+143% | $221K-62.1% | $19K+183% | $427K+360% | ||
| $20M— | —— | —— | —— | $0— | ||
| -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% | -$29.5M-41.8% | -$27.11M-58.6% | ||
| -$23.99M+10.7% | -$38.24M-64.4% | -$29.73M-38.8% | -$29.24M-42.0% | -$26.86M-58.6% | ||
| -$23.99M+10.7% | -$38.24M-64.4% | -$29.73M-38.8% | -$29.24M-42.0% | -$26.86M-58.6% | ||
| -119.9%— | —— | —— | —— | —— | ||
| -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% | -$29.5M-41.8% | -$27.11M-58.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rapport Therapeutics, Inc. profitable?
- Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $107.3M over the trailing twelve months.
- What is Rapport Therapeutics, Inc.'s earnings per share?
- Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.59.
- Where does Rapport Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.